Area of research
Genetics · Pulmonary and Respiratory Medicine
Research interest
Research interests include Glioma Diagnosis and Treatment, Brain Metastases and Treatment, Medical Imaging Techniques and Applications, and Radiomics and Machine Learning in Medical Imaging.
Can we make it up? - second-look surgery due to post-operative residual tumour in patients diagnosed with diffuse glioma
Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells
Flow cytometry identifies changes in peripheral and intrathecal lymphocyte patterns in CNS autoimmune disorders and primary CNS malignancies
Prognostic factors for overall survival in elderly patients with glioblastoma: Analysis of the pooled NOA-08 and Nordic trials with the CCTG-EORTC (CE.6) trial
Increased Distress in Neurooncological Patients, a Monocentric Longitudinal Study: When to Screen Which Patient?
Multiomics and spatial mapping characterizes human CD8 <sup>+</sup> T cell states in cancer
Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
The impact of preoperative MRI-based apparent diffusion coefficients on local recurrence and outcome in patients with cerebral metastases.
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial.
Psychooncological distress in low-grade glioma patients-a monocentric study.
Cost Effectiveness of <sup>18</sup>F-FET PET for Early Treatment Response Assessment in Glioma Patients After Adjuvant Temozolomide Chemotherapy.
Two Decades of Brain Tumour Imaging with O-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum Jülich Experience.
In-Vitro Use of Verteporfin for Photodynamic Therapy in Glioblastoma.
Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastoma.
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
Mid-term treatment-related cognitive sequelae in glioma patients.
First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas-a single-centre experience in 61 patients.
Synthetic vascular grafts as a new treatment option for space-occupying tumor bed cysts.
Would they do it again? Final treatment decisions in malignant brain tumour patients-a caregiver's perspective.
Evaluate the safety and efficacy of dura sealant patch in reducing cerebrospinal fluid leakage following elective cranial surgery (ENCASE II): study protocol for a randomized, two-arm, multicenter trial.
Impact of COVID-19 Epidemic on Psycho-Oncological Distress in Neuro-Oncological Patients.
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Early Treatment Response Assessment Using <sup>18</sup>F-FET PET Compared with Contrast-Enhanced MRI in Glioma Patients After Adjuvant Temozolomide Chemotherapy.
Telomerase reverse transcriptase promoter mutation– and O6-methylguanine DNA methyltransferase promoter methylation–mediated sensitivity to temozolomide in isocitrate dehydrogenase–wild-type glioblastoma: is there a link?
Overexpression of Cystine/Glutamate Antiporter xCT Correlates with Nutrient Flexibility and ZEB1 Expression in Highly Clonogenic Glioblastoma Stem-like Cells (GSCs)
Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine (<sup>18</sup>F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients.
Telomerase reverse transcriptase promoter mutation- and O<sup>6</sup>-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?